David R. Bauer

Davis Polk is advising The Ferrero Group on its $2.8 billion acquisition of Nestlé’s U.S. confectionary business. The transaction, which is subject to customary closing conditions and…

Davis Polk advised the underwriters in connection with an initial public offering of 15,972,221 shares of common stock of Denali Therapeutics Inc., including shares sold pursuant to the…

Davis Polk advised the sole book-running manager in connection with the $50 million follow-on offering of 1,970,000 shares of common stock of Editas Medicine, Inc. The common…

Davis Polk advised InflaRx N.V. on its $100 million initial public offering of 6,667,000 of its common shares. In addition, InflaRx has granted the underwriters a 30-day option to purchase…

Davis Polk advised the underwriters in connection with an initial public offering of 5,333,333 shares of common stock of Allena Pharmaceuticals, Inc., at $14.00 per share, for total gross…

Davis Polk advised the representatives of the several underwriters in connection with Ablynx NV’s offering of $230 million of its ordinary shares in the form of American Depositary…

Davis Polk advised the representatives of the underwriters in connection with the $122.4 million public offering of 4,800,000 shares of common stock by Flexion Therapeutics, Inc. The…

Davis Polk advised the underwriters in connection with an initial public offering of 7,500,000 shares of common stock of Deciphera Pharmaceuticals, Inc., at $17.00 per share, for total…

Davis Polk advised Kadmon Holdings, Inc. in connection with an $80.4 million offering of 22,275,000 shares of common stock and warrants to purchase 8,910,000 shares of common stock, which…

 Davis Polk advised the joint book-running managers in connection with an SEC-registered offering by Zoetis Inc. of $750 million aggregate principal amount of its 3.000% senior…